Date: 2011-10-05
Type of information: R&D agreement
Compound:
Company: Evotec (Germany) UCB (Belgium)
Therapeutic area: Immunology
Type agreement: research - R&D
Action mechanism:
Disease:
Details: Evotec has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology. As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against a selected number of targets. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate. Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals of the research collaboration with early stage discovery, preclinical and clinical milestones. In addition Evotec will receive royalties based on net sales of any approved drugs from the collaboration.
Financial terms: Financial terms were not disclosed.
Latest news:
